Tag: pulmonary drugs market demand

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Pulmonary Drugs Market Forecast: Value Set To Climb From $60.06 Billion To $74.13 Billion

The pulmonary drugs market has demonstrated significant growth over recent years. It is forecast to expand from $56.98 billion in 2025 to $60.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.4%. This historical expansion can be attributed to various factors including a rise in asthma prevalence, increased incidence of COPD, escalating urban air pollution, the broader implementation of inhalation drug delivery, and improved methods for diagnosing respiratory diseases.

The pulmonary drugs market is anticipated to experience robust expansion over the coming years. By 2030, its valuation is projected to reach $74.14 billion, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected increase during the forecast period stems from factors such as an expanding aging demographic, the broader availability of biologic pulmonary medications, the integration of precision respiratory medicine, a rise in conditions linked to smoking, and better access to inhaled treatments. Key developments expected within this period involve the increasing uptake of targeted respiratory solutions, the proliferation of combination inhalation treatments, an enhanced emphasis on managing diseases over the long term, the expansion of biologic-derived pulmonary pharmaceuticals, and a move towards individualized respiratory care.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=53625747&type=smp&name=Pulmonary%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pulmonary Drugs Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The expanding occurrence of respiratory ailments is anticipated to fuel the expansion of the pulmonary drugs market moving ahead. These disorders are defined as health conditions impacting the lungs and airways, hindering typical respiration and oxygen transfer. The rise in respiratory disorders is attributed to the increasing incidence of smoking, which causes lung damage and persistent illnesses. Pulmonary drugs are vital in handling respiratory disorders, as they enhance lung function, decrease inflammation, and alleviate airway blockages to facilitate easier breathing. To illustrate, in May 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the age-adjusted COPD prevalence among adults 18+ stood at 3.8%, with women exhibiting higher rates (4.1%) compared to men (3.4%). The prevalence of COPD showed a sharp increase with age, climbing from 0.4% in adults 18–24 to 10.5% in those 75 and older. Consequently, the escalation of respiratory diseases is stimulating the expansion of the pulmonary drugs market.

Pulmonary Drugs Market Segment Outlook: Which Categories Are Growing Fastest?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Pulmonary Drugs Market Innovation Trends Shaping Future Development

Leading firms within the pulmonary drugs market are concentrating on innovative therapeutic approaches, specifically dual PDE3 and PDE4 inhibition administered by inhalation. This aims to merge bronchodilator and non-steroidal anti-inflammatory properties into one molecule for managing chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition facilitates concurrent airway relaxation and a decrease in lung inflammation, tackling persistent COPD symptoms more efficiently than conventional treatments and streamlining administration by eliminating the need for intricate inhalation methods. As an example, in June 2024, Verona Pharma plc, a biopharmaceutical company from the UK, secured U.S. FDA approval for Ohtuvayre (ensifentrine). This product marks the initial inhaled therapy featuring such a dual-mechanism profile to be approved in more than 20 years. Administered through a standard jet nebulizer, Ohtuvayre offers both bronchodilator and anti-inflammatory advantages in a single dose. Its clinical effectiveness was demonstrated in the Phase 3 ENHANCE trials, both when used alone and alongside other maintenance treatments. The therapy is anticipated to be accessible via specialty pharmacies in the U.S. by the third quarter of 2024.

Pulmonary Drugs Market Leading Companies And Competitive Benchmarking

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

View The Full Pulmonary Drugs Market Report:

https://thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pulmonary Drugs Market Largest Region By Revenue And Market Share

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Pulmonary Drugs Market Size Forecast: How Large Could The Market Become By 2030?

The pulmonary drugs market has experienced robust expansion over recent years, with projections indicating growth from $56.98 billion in 2025 to $60.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.4%. This historical period’s progress was driven by factors such as a higher prevalence of asthma, an increasing incidence of chronic obstructive pulmonary disease (COPD), urban air pollution intensification, broader adoption of inhalation drug delivery systems, and enhanced diagnostic methods for respiratory conditions.

The pulmonary drugs market is projected to experience robust expansion over the coming years, with its value anticipated to reach $74.14 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.4%. This forecasted growth is driven by factors such as an increasing elderly population, the development of biologic pulmonary medications, the integration of precision respiratory medicine, a higher prevalence of smoking-related conditions, and enhanced availability of inhaled therapies. Key trends shaping the market during this period include a growing emphasis on targeted respiratory therapies, the emergence of combination inhalation products, a stronger focus on long-term disease management, the expansion of biologic-based pulmonary treatments, and a transition toward personalized respiratory care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pulmonary Drugs Market Growth Factors Supporting Long-Term Expansion

The pulmonary drugs market is experiencing growth driven by the rising prevalence of respiratory diseases, which impair normal breathing and oxygen exchange by affecting the lungs and airways. An increase in respiratory disorders is linked to factors such as higher smoking rates, which cause lung damage and contribute to chronic conditions, while pulmonary drugs are essential for managing these issues by enhancing lung function, reducing inflammation, and alleviating airway obstructions to facilitate better breathing. Data from the Centers for Disease Control and Prevention, a US-based government agency, indicated in May 2025 that in 2023, age-adjusted COPD prevalence among adults 18 and older stood at 3.8%, with rates higher in women at 4.1% compared to men at 3.4%, and this prevalence increased sharply with age from 0.4% in those aged 18–24 to 10.5% in individuals 75 and older. Consequently, the escalating incidence of respiratory diseases is fueling expansion in the pulmonary drugs market.

Pulmonary Drugs Market Segmentation And Category Breakdown

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Pulmonary Drugs Market Industry Trends Shaping Future Revenue Growth

Key players in the pulmonary drugs market are concentrating on therapeutic breakthroughs, including the use of inhaled dual PDE3 and PDE4 inhibition, which delivers both bronchodilator and non-steroidal anti-inflammatory effects in a single compound for long-term COPD management. This dual inhibition allows airway dilation and decreases lung inflammation simultaneously, tackling ongoing COPD symptoms more efficiently compared to conventional treatments and streamlining dosing without needing intricate inhalation methods. For example, in June 2024, Verona Pharma plc, a biopharmaceutical firm based in the UK, gained U.S. FDA approval for Ohtuvayre (ensifentrine), the first inhaled medication in over two decades to feature this dual-action mechanism. Administered with a standard jet nebulizer, Ohtuvayre offers bronchodilation and anti-inflammatory action in one dose, demonstrating clinical effectiveness as a standalone therapy or combined with other maintenance drugs in the Phase 3 ENHANCE trials, and is set to become accessible via U.S. specialty pharmacies by the third quarter of 2024.

Pulmonary Drugs Market Competitive Analysis Of Major Industry Participants

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pulmonary Drugs Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Pulmonary Drugs Market Between 2026 And 2030?

The pulmonary drugs market size has experienced significant growth in recent years. It is projected to expand from $56.98 billion in 2025 to $60.07 billion in 2026, registering a compound annual growth rate (CAGR) of 5.4%. The historical market expansion can be attributed to factors such as increasing asthma prevalence, rising COPD incidence, the growth of urban air pollution, the expansion of inhalation drug delivery methods, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is anticipated to exhibit robust growth over the next few years. It is projected to reach $74.14 billion in 2030, displaying a compound annual growth rate (CAGR) of 5.4%. This expansion in the forecast period can be attributed to an aging population’s growth, the spread of biologic pulmonary drugs, the adoption of precision respiratory medicine, an increase in smoking-related disorders, and improved access to inhaled therapies. Major trends expected during this period include a rising uptake of targeted respiratory treatments, the expansion of combination inhalation therapies, a heightened focus on long-term disease management, the broadening of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Key Growth Drivers Are Influencing The Pulmonary Drugs Market?

The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. These disorders are defined as health conditions impacting the lungs and airways, which hinder regular breathing and the exchange of oxygen. The rise in respiratory disorders is linked to the increasing rate of smoking, resulting in damage to the lungs and the development of chronic illnesses. Pulmonary drugs are vital in treating respiratory conditions by enhancing lung performance, diminishing inflammation, and easing airway blockages to facilitate improved respiration. As an illustration, in May 2025, the Centers for Disease Control and Prevention, a US-based government agency, stated that for 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, showing higher figures in women (4.1%) compared to men (3.4%). The prevalence of COPD climbed significantly with advancing age, escalating from 0.4% in adults 18–24 to 10.5% in those 75 and older. Consequently, the escalating number of respiratory diseases is stimulating the expansion of the pulmonary drugs market.

What Are The Major Segment Categories Within The Pulmonary Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Trends Are Impacting The Pulmonary Drugs Market?

Companies operating in the pulmonary drugs market are prioritizing therapeutic advancements, notably focusing on dual PDE3 and PDE4 inhibition delivered via inhalation. This innovation seeks to integrate bronchodilator and non-steroidal anti-inflammatory benefits into a single molecule for the sustained management of chronic obstructive pulmonary disease (COPD). Dual PDE3 and PDE4 inhibition facilitates simultaneous airway relaxation and decreased lung inflammation, thereby more effectively addressing persistent COPD symptoms than conventional treatments and streamlining administration. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, obtained U.S. FDA approval for Ohtuvayre (ensifentrine), representing the first inhaled therapy with this dual-mechanism profile in over 20 years. Delivered via a standard jet nebulizer, Ohtuvayre provides both bronchodilator and anti-inflammatory effects in one dose, having shown clinical efficacy as a monotherapy and in conjunction with other maintenance treatments in the Phase 3 ENHANCE trials, and is projected to be accessible through specialty pharmacies in the U.S. by the third quarter of 2024.

Which Companies Are Influencing The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Is The Largest Regional Market In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pulmonary Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Pulmonary Drugs Market During 2026–2030?

The pulmonary drugs market has demonstrated substantial growth over recent years. Its valuation is anticipated to climb from $56.98 billion in 2025 to $60.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.4%. This past expansion can be primarily attributed to factors including increasing asthma prevalence, rising COPD incidence, the growth of urban air pollution, the expansion of inhalation drug delivery, and enhanced diagnosis of respiratory diseases.

The pulmonary drugs market is anticipated to experience robust expansion in the coming years. This market is projected to reach $74.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this growth during the forecast period include an expanding aging population, the proliferation of biologic pulmonary drugs, wider adoption of precision respiratory medicine, a rise in smoking-related illnesses, and enhanced availability of inhaled treatments. Key trends anticipated for the forecast duration encompass a growing embrace of targeted respiratory therapies, the development of combination inhalation treatments, an increased emphasis on managing diseases for the long term, the broadening scope of biologic-based pulmonary medications, and a movement towards individualized respiratory care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Drivers Are Supporting The Pulmonary Drugs Market Growth?

The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. Respiratory disorders are defined as health conditions impacting the lungs and airways, thereby hindering regular breathing and the exchange of oxygen. These disorders are on the rise, primarily attributed to the widespread increase in smoking, which results in lung damage and chronic ailments. Pulmonary drugs are vital in addressing respiratory disorders, as they enhance lung function, decrease inflammation, and alleviate airway blockages, facilitating improved respiration. As an illustration, in May 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the age-adjusted prevalence of COPD among adults 18+ stood at 3.8%, with women exhibiting higher rates (4.1%) compared to men (3.4%). The occurrence of COPD sharply escalated with advancing age, climbing from 0.4% in adults 18–24 to 10.5% in individuals 75 and older. Consequently, the surge in respiratory diseases is propelling the growth of the pulmonary drugs market.

Which Segments Define The Pulmonary Drugs Market Segment Structure?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Which Trends Are Shaping Growth In The Pulmonary Drugs Market?

Leading companies within the pulmonary drugs market are concentrating on therapeutic advancements, such as the combined PDE3 and PDE4 inhibition delivered via inhalation, aiming to merge bronchodilator and non-steroidal anti-inflammatory actions into a single compound for the ongoing management of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition simultaneously promotes airway relaxation and reduces lung inflammation, addressing persistent COPD symptoms more effectively than existing treatments and simplifying administration without the need for intricate inhalation techniques. As an illustration, in June 2024, Verona Pharma plc, a biopharmaceutical company based in the UK, secured U.S. FDA approval for Ohtuvayre (ensifentrine), which is the first inhaled treatment with this dual-mechanism characteristic in over 20 years. Administered through a standard jet nebulizer, Ohtuvayre offers both bronchodilator and anti-inflammatory advantages in a single dose, proving its clinical effectiveness as a standalone therapy and when combined with other maintenance treatments in the Phase 3 ENHANCE trials, with availability through specialty pharmacies in the U.S. projected by the third quarter of 2024.

Who Are The Established Players Within The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Get The Full Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Has The Greatest Market Share In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pulmonary Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Pulmonary Drugs Market By 2030 Starting From Its 2026 Size?

The pulmonary drugs market size has experienced significant growth in recent years. It is anticipated to expand from $56.98 billion in 2025 to $60.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.4%. This historical expansion can be attributed to factors such as the increasing prevalence of asthma, a rise in COPD incidence, growing urban air pollution, the expansion of inhalation drug delivery systems, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is anticipated to experience substantial growth in the upcoming years, with projections indicating it will expand to $74.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.4%. This expansion during the forecast period is primarily attributed to factors such as an increasing aging population, the proliferation of biologic pulmonary drugs, the adoption of precision respiratory medicine, a rise in smoking-related disorders, and improved access to inhaled therapies. Significant trends expected during this period encompass a growing uptake of targeted respiratory treatments, the development of combination inhalation therapies, an increased focus on long-term disease management, the widening availability of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Pulmonary Drugs Market?

The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. These disorders are defined as health conditions impacting the lungs and airways, hindering regular respiration and gas exchange. The rise in respiratory disorders is linked to the increasing rate of smoking, which results in lung damage and long-term illnesses. Pulmonary medications are vital for treating respiratory conditions, as they enhance lung function, decrease inflammation, and alleviate blockages in the airways, facilitating improved breathing. For example, data from May 2025 by the US-based government agency, the Centers for Disease Control and Prevention, indicated that in 2023, the age-adjusted prevalence of COPD among adults 18+ stood at 3.8%, with women experiencing a higher rate (4.1%) compared to men (3.4%). The prevalence of COPD also significantly escalated with age, climbing from 0.4% in individuals aged 18–24 to 10.5% in those 75 and older. Consequently, the growing incidence of respiratory ailments is serving as a key driver for the expansion of the pulmonary drugs market.

Which Segment Categories Define The Pulmonary Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Major Market Trends Are Driving Changes In The Pulmonary Drugs Market?

Leading firms within the pulmonary drugs market are prioritizing novel therapeutic approaches, specifically dual PDE3 and PDE4 inhibition administered by inhalation, aiming to integrate both bronchodilator and non-steroidal anti-inflammatory actions into one compound for the ongoing management of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition facilitates concurrent relaxation of the airways and a decrease in lung inflammation, thus more effectively managing persistent COPD symptoms compared to conventional treatments and streamlining delivery by eliminating the need for intricate inhalation methods. As an example, in June 2024, Verona Pharma plc, a biopharmaceutical company headquartered in the UK, obtained U.S. FDA approval for Ohtuvayre (ensifentrine), notable as the first inhaled therapy demonstrating this dual-mechanism approach in over 20 years. Administered through a standard jet nebulizer, Ohtuvayre delivers both bronchodilator and anti-inflammatory advantages in one dose, having demonstrated clinical effectiveness as a standalone treatment and when combined with other ongoing therapies during the Phase 3 ENHANCE trials, with anticipated availability via specialty pharmacies in the U.S. by the third quarter of 2024.

Who Are The Top Companies Competing In The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Read the full pulmonary drugs market report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Regions Are Projected To Dominate The Pulmonary Drugs Market In The Coming Years?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pulmonary Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pulmonary drugs market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Pulmonary Drugs Market between 2026 and 2030?

The pulmonary drugs market has experienced substantial growth in recent years. It is expected to expand from $56.98 billion in 2025 to $60.07 billion in 2026, at a compound annual growth rate (CAGR) of 5.4%. The growth witnessed in the past can be attributed to an increase in asthma prevalence, rising COPD incidence, the proliferation of urban air pollution, the expansion of inhalation drug delivery, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is poised for robust expansion in the coming years. It is projected to reach $74.14 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period can be attributed to an increasing aging population, the broadening availability of biologic pulmonary drugs, the integration of precision respiratory medicine, a rise in smoking-related ailments, and improved access to inhaled therapies. Significant trends expected in this period include the growing acceptance of targeted respiratory therapies, the proliferation of combination inhalation treatments, an intensified focus on long-term disease management, the expansion of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Drivers Are Expected To Impact The Pulmonary Drugs Market During The Forecast Period?

The escalating occurrence of respiratory diseases is projected to boost the pulmonary drugs market’s growth in the future. Respiratory disorders are defined as medical conditions that impact the lungs and airways, hindering normal breathing and oxygen exchange. The rise in these disorders is largely due to the increasing prevalence of smoking, which leads to lung damage and various chronic diseases. Pulmonary drugs are essential for managing respiratory disorders by improving lung function, decreasing inflammation, and relieving airway obstruction, thereby facilitating better breathing. For instance, in May 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). Furthermore, COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the growing incidence of respiratory illnesses is a key driver for the expansion of the pulmonary drugs market.

How Is The Pulmonary Drugs Market Divided Into Segments?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

How Are New Market Trends Shaping The Landscape Of The Pulmonary Drugs Market?

Major companies in the pulmonary drugs market are focusing on therapeutic innovations, such as the inhaled delivery of dual PDE3 and PDE4 inhibition, to combine bronchodilator and non-steroidal anti-inflammatory effects within a single molecule for the continuous treatment of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition allows for simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), which is the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, demonstrating clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

Which Major Firms Are Strengthening Their Position In The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pulmonary Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pulmonary drugs market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Pulmonary Drugs Market between 2026 and 2030?

The pulmonary drugs market has experienced substantial growth in recent years. It is expected to expand from $56.98 billion in 2025 to $60.07 billion in 2026, at a compound annual growth rate (CAGR) of 5.4%. The growth witnessed in the past can be attributed to an increase in asthma prevalence, rising COPD incidence, the proliferation of urban air pollution, the expansion of inhalation drug delivery, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is poised for robust expansion in the coming years. It is projected to reach $74.14 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period can be attributed to an increasing aging population, the broadening availability of biologic pulmonary drugs, the integration of precision respiratory medicine, a rise in smoking-related ailments, and improved access to inhaled therapies. Significant trends expected in this period include the growing acceptance of targeted respiratory therapies, the proliferation of combination inhalation treatments, an intensified focus on long-term disease management, the expansion of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Drivers Are Expected To Impact The Pulmonary Drugs Market During The Forecast Period?

The escalating occurrence of respiratory diseases is projected to boost the pulmonary drugs market’s growth in the future. Respiratory disorders are defined as medical conditions that impact the lungs and airways, hindering normal breathing and oxygen exchange. The rise in these disorders is largely due to the increasing prevalence of smoking, which leads to lung damage and various chronic diseases. Pulmonary drugs are essential for managing respiratory disorders by improving lung function, decreasing inflammation, and relieving airway obstruction, thereby facilitating better breathing. For instance, in May 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). Furthermore, COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the growing incidence of respiratory illnesses is a key driver for the expansion of the pulmonary drugs market.

How Is The Pulmonary Drugs Market Divided Into Segments?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

How Are New Market Trends Shaping The Landscape Of The Pulmonary Drugs Market?

Major companies in the pulmonary drugs market are focusing on therapeutic innovations, such as the inhaled delivery of dual PDE3 and PDE4 inhibition, to combine bronchodilator and non-steroidal anti-inflammatory effects within a single molecule for the continuous treatment of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition allows for simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), which is the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, demonstrating clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

Which Major Firms Are Strengthening Their Position In The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pulmonary Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the benzodiazepine drugs market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Benzodiazepine Drugs Industry By 2029?

The pulmonary drugs market has shown consistent expansion in its size over recent years. It is anticipated to increase from $54.28 billion in 2024 to $56.98 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.0%. Historically, this growth can be attributed to a rise in the prevalence of respiratory diseases, an increase in smoking rates, the growing geriatric population, the expansion of healthcare access, and a surge in pollution levels.

The pulmonary drugs market size is anticipated to undergo significant expansion in the coming years. This market is projected to reach $70.35 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.4%. The expansion over the forecast period is primarily driven by factors such as the development of healthcare infrastructure, an increasing prevalence of cardiovascular disease, the wider availability of homecare treatments, increased understanding of pulmonary diseases, and a rise in asthma cases. Prominent trends expected during this period include advancements in technology, AI-driven approaches to drug discovery, the integration of smart inhalers, the development of nanotechnology-based formulations, and breakthroughs in gene therapy.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Major Drivers Are Impacting The Benzodiazepine Drugs Market?

The escalating occurrence of respiratory conditions is anticipated to fuel the expansion of the pulmonary drugs market moving forward. Respiratory disorders are medical issues that impact the lungs and airways, thereby hindering normal breathing and oxygen exchange. These disorders are on the rise, primarily due to the increasing prevalence of smoking, which results in lung damage and chronic diseases. Pulmonary drugs are essential for managing respiratory disorders, as they improve lung function, diminish inflammation, and relieve airway obstruction, promoting better breathing. For instance, in November 2023, the Bureau of Labor Statistics, a US-based government agency, reported that the illness rate among private industry employers in 2022 climbed to 45.2 cases per 10,000 FTE workers, an increase from 37.7 cases in 2021. This surge was predominantly linked to a higher incidence of respiratory illnesses, which went up from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Thus, the growing prevalence of respiratory diseases is driving the growth of the pulmonary drugs market.

Which Segment Categories Are Driving Maximum Growth In The Benzodiazepine Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Which Long-Term Trends Will Play A Crucial Role In The Benzodiazepine Drugs Market?

Leading companies within the pulmonary drugs market are focusing on developing innovative therapies, such as single-inhaler triple therapy (SITT), to enhance treatment efficacy, improve patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy (SITT) is a treatment that combines three different medications in a single inhaler to manage chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), more effectively. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Trelegy Ellipta, which was India’s first single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary disease (COPD). This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom exacerbations. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.

Who Are The Dominant Players In The Benzodiazepine Drugs Market Today?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Is At The Forefront Of Innovation In The Benzodiazepine Drugs Market?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Benzodiazepine Drugs Market 2025, By The Business Research Company

Pulmonologists Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonologists-global-market-report

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Pulmonary Drugs Industry In 2025?

The pulmonary drugs market size has shown consistent expansion in recent years. Its value is expected to rise from $54.28 billion in 2024 to $56.98 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. The upward trend observed historically can be credited to factors such as the increasing prevalence of respiratory diseases, the rise in smoking rates, the growing geriatric population, the broadening of healthcare access, and the surge in pollution levels.

The pulmonary drugs market size is anticipated to undergo significant expansion in the forthcoming years. It is projected to increase to $70.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is due to factors such as expanding healthcare infrastructure, an increasing prevalence of cardiovascular disease, the spread of homecare treatments, heightened awareness about pulmonary diseases, and a rising occurrence of asthma. Prominent trends for the forecast period include advancements in technology, AI-driven approaches to drug discovery, the adoption of smart inhalers, nanotechnology-based formulations, and developments in gene therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Pulmonary Drugs Industry?

The growing occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. Respiratory disorders are defined as health conditions impacting the lungs and airways, hindering typical breathing and oxygen exchange. The rise in respiratory disorders stems from the increasing incidence of smoking, which causes lung damage and long-term illnesses. Pulmonary drugs are essential for managing respiratory conditions by enhancing lung performance, decreasing inflammation, and alleviating airway blockages to facilitate easier breathing. As an illustration, data from November 2023, provided by the Bureau of Labor Statistics, a US-based government agency, indicated that the illness rate among private industry employers climbed to 45.2 cases per 10,000 FTE workers in 2022, rising from 37.7 cases in 2021. This increase was primarily linked to a greater incidence of respiratory illnesses, which rose from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalation of respiratory diseases is propelling the expansion of the pulmonary drugs market.

How Is The Pulmonary Drugs Market Classified Into Different Segments?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Which Competitive Trends Are Defining The Pulmonary Drugs Market Structure?

Leading companies operating within the pulmonary drugs market are prioritizing the development of innovative therapies, such as single-inhaler triple therapy (SITT), to improve treatment efficacy, enhance patient adherence, and simplify medication regimens for more effective disease management. Single-inhaler triple therapy (SITT) is a treatment designed to combine three distinct medications in a single inhaler, aiming to more effectively manage chronic respiratory diseases like chronic obstructive pulmonary disease (COPD). For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, launched Trelegy Ellipta, representing India’s first single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary disease (COPD). This therapy incorporates fluticasone furoate, umeclidinium, and vilanterol to boost lung function and decrease the frequency of symptom exacerbations. The advanced Ellipta inhaler ensures accurate dosing and promotes better patient adherence when compared to treatment plans involving multiple inhalers. Given that India has over 100 million COPD patients, this launch aims to streamline treatment and enhance patient outcomes.

Who Are The Prominent Global Companies Shaping The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Do Regional Market Performances Compare Within The Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2025, By The Business Research Company

Pulmonologists Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonologists-global-market-report

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model